BOSTON , Oct. 02, 2019 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. , a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced the pricing of its initial public offering of 5,666,667 shares